U.S. Markets closed

Acer Shares Down on FDA's CRL for Genetic Disorder Treatment

Zacks Equity Research

Shares of Acer Therapeutics Inc. ACER slumped more than 75% after it received a Complete Response Letter (CRL) from the FDA regarding its new drug application (NDA) for Edsivo (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS). Ehlers-Danlos Syndrome (“EDS”) is an inherited disorder caused by mutations in the genes responsible for the structure, production, or processing of collagen.

In the CRL, the FDA has asked the company to conduct an adequate and well-controlled study to determine whether Edsivo reduces the risk of clinical events in patients with vEDS. Acer plans to request a meeting with the FDA to discuss its response. The company expects to respond to the FDA in the third quarter of 2019. The CRL implies a delay in the approval of Edsivo.

Edsivois a selective adrenergic modulator and is currently approved in the European Union for the treatment of hypertension and angina.

Edsivo has an Orphan Drug exclusivity designation in the United States for the vEDS indication.

The company also has other candidates in its pipeline. Its ACER-001 is a fully taste-masked, immediate release formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders (“UCD”) and Maple Syrup Urine Disease (“MSUD”).  The company expects to submit an NDA for ACER-001 in UCD in the fourth quarter of 2019. The company also has osanetant in its pipeline, which is being evaluated for the treatment of various neuroendocrine disorders. An investigational new drug (“IND”) application for the drug is anticipated in the second half of 2019.

ACER Therapeutics, Inc. Price

 

Opexa Therapeutics, Inc. Price

Acer Therapeutics, Inc. price | Acer Therapeutics, Inc. Quote

Zacks Rank and Stocks to Consider

Acer currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks are Cumberland Pharmaceuticals Inc. CPIX, Evotec AG EVTCY and Neos Therapeutics Inc. NEOS, each carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Cumberland’s earnings per share estimates have moved up from 7 cents to 46 cents for 2020 in the past 60 days. The company beat estimates in the trailing four quarters, the average being 137.17%.         

Evotec’s earnings per share estimates have moved up from 90 cents to $1.03 for 2019 and from 97 cents to $1.37 for 2020 in the past 60 days. 

Neos’ loss per share estimates have narrowed from 66 cents to 61 cents for 2019 in the past 60 days. The company outpaced estimates in two of the trailing four quarters, the average being 2.85%.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Neos Therapeutics, Inc. (NEOS) : Free Stock Analysis Report
 
Evotec AG (EVTCY) : Free Stock Analysis Report
 
Cumberland Pharmaceuticals Inc. (CPIX) : Free Stock Analysis Report
 
Opexa Therapeutics, Inc. (ACER) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research